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Abstract
Personalized medicine is a new approach that allows the identification of 
patients that can benefit from targeted therapies because of the molecular char-
acteristics of the tumors they present. The molecular profile of the tumor can be 
studied at the genomic (DNA), transcriptomic (RNA) or protein (protein) level. 
The next generation sequencing is a useful tool for the study of molecular profile 
from DNA/RNA. This tool requires molecular pathologists highly trained in pre-
analytic processes, tumor area microdissection for tumor cell enrichment, method-
ology analysis and results. The in-depth study of molecular alterations in patients 
allows optimizing molecular diagnosis and selecting candidates for receive novel 
treatments against specific molecular targets. These patients are expected to benefit 
from multidisciplinary approach and learning. The aim of this chapter is to show 
the implications of molecular pathology in personalized medicine with an actual 
approach from the methodological limitations of formalin-fixed paraffin embedded 
(FFPE) tissues and their pre-analytical conditions.
Keywords: molecular pathology, personalized medicine, next generation sequencing, 
NGS, clinical benefit, multidisciplinary approach
1. Introduction
Personalized medicine is a new approach that allows the identification of 
patients that can benefit from targeted therapies, since the molecular characteristics 
of their tumors could be identified. Over the last decade, new drugs have been 
incorporated into the treatment, including the development of immunotherapy and 
treatment against specific molecular targets [1]. Thus, patients can receive specific 
treatments according to the biology of their tumor, turning oncology a tool for per-
sonalized medicine. In order to do so, the development of new DNA/RNA sequenc-
ing technologies was required, as well as the development of specific antibodies 
identifying mutated or altered proteins, and the design of new in situ hybridization 
techniques. The latter has enabled the selection via genetic biomarkers of patients, 
who can benefit from therapies targeted against specific molecular alterations [2]. 
Based on the detection of these point molecular alterations, with a clear oncogenic 
role, treatments have been developed to block the activation of mutated, ampli-
fied proteins or product of translocations by specific drugs. The identification of 
patients with therapeutic molecular targets in their tumors is currently a standard 
of care. Notwithstanding that, the initial morphological diagnosis and the eventual 
tumor classification by immunohistochemistry (IHC), as well as the acquisition, 
handling and processing of tumor tissue play a pivotal role.
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In advanced-stage patients, a relatively small amount of tissue obtained at a single 
procedure must be used most efficiently for all studies [3]. In this sense, consensus 
exists about making histopathological diagnosis using as little material as possible, 
which should be kept for molecular studies [4, 5]. The combination of less invasive 
techniques that provide very small samples to carry out an increasing number of deter-
minations is controversial, since it does not allow to increase the amount of tumor cells. 
Consequently, more sensitive and specific molecular determinations are required [6].
Although several methods are being developed, such as free tumor DNA detec-
tion in peripheral blood, most of these determinations are currently experimental 
and few are validated for clinical use [7, 8]. Therefore, until more sophisticated 
techniques for these and other molecular markers are validated, the amount/size of 
the samples should be considered.
The aim of this chapter is to show the implications of molecular pathology in 
personalized medicine with an actual approach from the methodological limita-
tions of formalin-fixed paraffin embedded (FFPE) tissues and their pre-analytical 
conditions.
2. Pre-analytical processes
In molecular pathology, several variables should be considered for optimal 
results, and pre-analytical conditions are evaluated.
2.1 Cold ischemia
One of the crucial phases in tissue management is the period of time immedi-
ately after the sample is extracted from the patient until it is placed in a fixation 
solution (cold ischemia). In an experimental animal model, significant differences 
in pH values were found between organs at the same cold-ischemia time, and in the 
same organ at different times. However, no differences were seen in the RNA quality 
assessed by its integrity number or absorbance ratios [9]. These results reveal a 
high pH in tissues undergoing ischemia. Firstly, although RNA integrity number 
(RIN) is a powerful tool to analyze the ribosomal profile and to further infer RNA 
quality from fresh and frozen tissues (and to compare samples RIN values given the 
same organism/tissue/extraction method), it is not enough to predict the integrity 
of mRNA transcripts or to describe the real biological conditions. Secondly, acidic 
duodenal pH has been reported to alter gene expression in the pancreas of a cystic 
fibrosis mouse. Upon correction of duodenal pH, either genetically (breeding 
CFTR-null with gastrin-null mice) or pharmacologically (proton pump inhibitor 
omeprazole), expression levels of genes measured by quantitative RT-PCR were 
significantly normalized [10]. Whether alkalosis is secondary to ischemic cell 
damage, or it may contribute to ischemic cell damage, is yet unknown. Thus, tissue 
alkalosis in cold-ischemia time may be an underlying mechanism of gene expres-
sion changes. Therefore, tissue-pH regulation after organ removal may minimize 
biological stress in human tissue samples. To date, no consensus exists about the 
optimal preservation solution. Further optimization of the composition of preser-
vation solutions is required to prolong organ preservation time, and to maximize 
the yield of successful transplantations by improving the quality and function of 
organs [11]. Most laboratories have neither control nor record of how long it takes 
between tissue removal and immersion in the fixer, and its arrival in the laboratory. 
In addition, most automatic tissue processor machines include a fixation step that 
further increases the fixation time, which is not often considered.
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2.2 Tissue fixation
Once the tissue has been obtained it should be fixed and 10% Neutral 
buffered formalin (NBF) fixation is recommended. Pre-fixation in alcohol-
based fixative, decalcifying acidic solutions, acidic fixatives (such as Bouin) 
or those containing metallic salts may alter DNA antigenicity or integrity. 
Setting a period of more than 6 hours and less than 48 hours is recommended 
[12]. Short or excessive fixation time may have deleterious effects on DNA and 
protein antigenic epitopes [13, 14]. The most frequently described effect of 
formalin in DNA is its fragmentation into small pieces. The use of polymerase 
chain reaction (PCR) techniques in formalin fixed paraffin embedded (FFPE) 
tissues is associated with a higher incidence of sequence artifacts and risk of 
misinterpretation in PCR results, compared with the use of fresh samples [15, 
16]. After the inclusion of the tissue in paraffin, the sample remains stable and 
is preserved against oxidative damage or other degenerative effects. However, in 
addition to fixation, the type of storage is another documented source that can 
damage DNA and cause artifacts in the PCR. For a better preservation of DNA, 
FFEP blocks should be stored below 27°C in humidity-free conditions. Although 
humidity can affect DNA stability, the acceptable humidity control range is not 
described. In our experience, up to ten-year-old FFEP blocks have been used. 
Provided that storage is accurately done and the pre-analytical parameters 
indicated in this chapter are met, blocks can be preserved up to this time [17]. 
Since FFPE tissue is currently used for genetic analysis, results should always 
be carefully interpreted. Mutations detected from FFPE samples by sequencing 
must be confirmed by independent PCR reaction. Determining the nature and 
duration of fixation is a great challenge to pathology laboratory, which receives 
samples from other centers. Therefore, it was suggested that the cold ischemia 
time, the type and time of tissue fixation should be registered in the pathology 
report [18].
3. Tumor area microdissection for tumor cell enrichment
For a molecular analysis, the following data are required: type of biopsy (pri-
mary tumor or metastasis), type of block, and percentage of tumor cells needed for 
each method.
3.1 PCR amplicon size
As above mentioned, fixation breaks the genetic material into small fragments, 
and then PCR of FFPE tissue needs a design of specific-sequences primers that 
flank targets with molecular weight less than 300 bp. Should the designed prim-
ers flank a fragmented-amplicon, they fail to perform the enzyme amplification 
because they need the continuity of the DNA/RNA mold to generate a strand, thus 
leading to lower sensitivity or false-negative results. Thus, the input for a PCR reac-
tion performed from FFPE tissue requires mandatory quantification with DNA/
RNA calculator spectrophotometer. Thus, each methodology uses a different sample 
input to obtain the analytical sensitivity (LOD). Every PCR requires a balance 
between its reaction components, and then the sample input has a direct relation-
ship with the concentration of the primers.
Therefore, somatic mutations, which are generated in tumors and are not pres-
ent in normal cells, require a minimum percentage for each method.
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3.2 Tumor cell enrichment
Based on the premise that somatic mutations occur, for the most part, in one of 
the alleles present in human genome, knowing that in humans there are two equal 
alleles on somatic chromosomes, one of maternal and one of paternal origin, we 
must understand that if we seek a tumor marker, we must enrich our input in this 
allele (Figure 1).
Sequencing of tumors is now routine and guides personalized cancer therapy. 
Mutant allele fractions (MAFs, or the ‘mutation dose’) of a driver gene may reveal 
the genomic structure of tumors and influence response to targeted therapies [19]. 
Mutation fraction can be defined as the ratio between mutant and wild-type (wt) 
alleles in a tumor sample. Allelic fraction is generally applied to a single muta-
tion in a tumor, and is therefore distinct from allelic frequency, which examines 
the frequency of an allele in a population. To date, however, these terminuses are 
unfortunately exchanged. Dideoxynucleotide sequencing is a routine method for 
identifying genetic changes. Since both alleles are amplified in this method, enough 
input of mutant allele (as compared to the input of normal allele) must be detected. 
However, this detection requires at least 10–20% of allelic presence. Mutations 
below this threshold due to normal cells high contamination or tumor heterogeneity 
could not be detected by this method [20]. Low percentages of neoplastic cells are 
sometimes associated with unreliable results. Therefore, the percentage of tumor 
cells must be estimated either through microdissection technique or selection of 
block interest region [5, 21]. The normal tissue and the lymphocyte infiltration areas 
must be removed from the tissue for analysis since both are nucleated elements 
that provide normal DNA. Areas of necrosis should be also removed, since the cell 
causing necrosis cannot be identified and may be normal or neoplastic. As we know, 
cell/tumor free DNA drained by biological mechanisms such as secretion, apoptosis 
and necrosis can be amplified by new generation methods that require smaller chain 
fragments, this allows us to infer that necrotic cell DNA can be amplified too, con-
sidering that an amount of intact nucleic acid chains still present in necrotic masses, 
unknowing the normal/tumor cell origin. In case microdissection is performed, 
higher sensitivity is obtained and more chance to detect a tumor specific mutation.
Depending on the method of extraction, hematic areas might be removed. 
However, they fail to provide normal DNA, because they are anucled cells, but hemo-
globin is one of the main polymerase inhibitors in PCR [22]. Regarding the use of clots, 
a DNA purification method is required to extract hemoglobin. In this sense, specific 
columns for FFPE tissues are of value. In several cases, Fine Needle Aspiration (FNA) 
is the first (and often the sole) diagnostic technique, given its low invasiveness, with 
Figure 1. 
Mutant allele fractions (MAFs, or the ‘mutation dose’).
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the clot being all the material available for molecular studies. Here formalin fixation 
is recommended, and although some reports propose 70% ethanol as an alternative, 
as above mentioned, DNA antigenicity or integrity may be altered by alcohol-based 
fixatives [5, 6, 23]. To increase the sensitivity of Sanger sequencing, and to discrimi-
nate from technical background, at least 70% of tumor cells are required [5]. The 
chromatogram obtained failed to discriminate specific signal from background. Such 
chromatogram type may be determined by pre-analytical conditions (pre-fixing, 
fixative type or fixation time).
As expected, there was a statistically significant difference between large 
and small samples DNA concentration. However, no significant differences were 
observed in concentration, fragments number or tumor initial percentage among 
different small sample types [18]. We can infer that all these types of tissue samples 
are similarly useful and depend on interdisciplinary medical team (surgeons, 
radiologists, clinicians, pathologists and oncologists) [6]. Large samples are blocks 
from surgical specimens, while small samples could be a core biopsy (yielding 
tissue samples approximately 1 mm in diameter), biopsies from bronchoscopy, 
nodal biopsies obtained by mediastinoscopy, and fine needle aspiration resulting in 
cytological specimens and clots. However, no significant differences were observed 
in concentration, fragments number or tumor initial percentage among different 
small sample types. Figure 2 shows that the amount of tissue obtained from small 
biopsies is often inadequate for a complete evaluation [18].
Over the last decade, genomic research of various solid tumors has suddenly 
progressed through the discovery of several molecular biomarkers that eventually 
impact on the prognosis and treatment of most common cancers. Recent technical 
innovations, such as “next or second generation” sequencing or “massively parallel” 
sequencing, have the potential to detect many abnormalities in a single assay, and 
are probably the solution to tissue shortage [24, 25].
This definitely results into multiple activities for surgeons and pathologists, who 
must obtain and process samples, write a pathology report, choose the material for 
molecular biology. In furtherance, those molecular biosciences technicians performing 
studies must draw up guidelines to standardize these practices, and algorithms to cover 
cyto- and histopathological diagnoses, IHC and molecular studies [4, 5, 23, 24, 26].
Figure 2. 
Performance of IHC and molecular study of large and small biopsies.
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4. Methodological analysis and results
Detection of tumor-derived mutations in FFPE is challenging because the tumor 
DNA is often scarce, fragmented, at a very low concentration and diluted by the 
presence of a background of non-mutant DNA (both tumor and non-tumor origin). 
Once the area of tumor cells is selected to be processed, the method of purification 
of the macromolecules must be chosen. Although manual non-expensive forms 
(phenol-chloroform-PK) exist, they fail to provide the necessary amount and 
quality of DNA. There are affinity columns for DNA, RNA or DNA/RNA together, 
which can be used on a low scale; and finally automated nucleic acid extraction 
equipment. Some years ago manual extraction was used for FFPE tissue because 
the columns were developed only for fresh samples. In the last decade the advent of 
personalized medicine boosted the development of new methodologies for this pur-
pose. Heydt et al. used FFPE tissue samples for the comparison of five automated 
DNA extraction systems, the BioRobot M48, the QIAcube and the QIAsymphony 
SP all from Qiagen (Hilden, Germany), the Maxwell 16 from Promega (Mannheim, 
Germany) and the InnuPure C16 from Analytik Jena (Jena, Germany). The results 
revealed that the Maxwell 16 from Promega seems to be the superior system for 
DNA extraction from FFPE material. This study also evaluated DNA quantifica-
tion systems using the three most common techniques, UV spectrophotometry, 
fluorescent dye-based quantification, and quantitative PCR. The comparison of 
quantification methods showed inter-method variations, but all methods could 
be used to estimate the right amount for PCR amplification and for massively 
parallel sequencing. DNA extracts were quantified as follows: NanoDrop 2000c 
spectrophotometer (Thermo Fisher Scientific), Quant-iT dsDNA HS Assay on the 
Qubit 2.0 fluorometer (Life Technologies), QuantiFluor dsDNA Sample Kit on the 
QuantiFluor-ST fluorometer (Promega) and Quant-iT Pico-Green dsDNA reagent 
(Life Technologies) on the LightCycler 480 Instrument (Roche). No difference was 
observed in mutation analysis based on the results of the quantification methods. 
These findings emphasize that it is particularly important to choose the most 
reliable and constant DNA extraction system, especially when using small biopsies 
and low elution volumes [27]. Once DNA/RNA has been obtained and quantified, 
analysis requires highly sensitive and specific assays. Different techniques with their 
own advantages and disadvantages can be used to identify and monitor mutations.
4.1 Real-time qPCR assays
A real-time PCR or quantitative PCR (qPCR) amplifies, both quantitatively and 
semi-quantitatively, a targeted DNA molecule during the PCR process. There exist at 
least two methods for the detection of PCR products: non-specific fluorescent dyes 
that bind double-stranded DNA molecules by intercalating between the DNA bases. 
This method is used in qPCR because the fluorescence can be measured at the end of 
each amplification cycle to determine, either relatively or absolutely, how much DNA 
has been amplified. The other method is sequence-specific DNA probes consisting of 
oligonucleotides that are labeled with a fluorescent reporter, which permits detection 
only after hybridization of the probe with its complementary sequence (TaqMan).
There is also a revolutionary method that uses PlexZyme™ technology. The 
revolution in this technology is given by a structure called partzyme (A and B). 
Each partzyme has 3 different regions: (I) the region that joins the target sequence 
of DNA, (II) the catalytic constituent region, and (III) the region that joins the 
probe. Once the primers generate the amplicons, both partzymes join their comple-
mentary sequences through the region (I), acquiring a characteristic structure 
thanks to the region (II) that allows the region (III) to be exposed. The fluorescently 
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labeled reporter probe also binds to the partzymes in the region (III) exposed, and 
once the active catalytic core is formed, the probe is cleaved, producing a signal 
that is indicative of successful amplification of the target gene. This technology can 
produce a robust quintuplex with five target assays into a single reaction tube that 
contained 10 partzymes (5 A and 5 B), 10 primers (5 forwards and 5 revers), and 5 
probes, with a 5 different fluorophores. All consumables required for sample prepa-
ration and RT-PCR amplification and detection are provided in a single cartridge 
loaded into the Idylla™ system. Handling time is less than two minutes per sample, 
with the liquid-tight, disposable cartridges greatly reducing the risk of contamina-
tion (Biocartis NV, Belgium).
4.2 ddPCR assay
In the non-sequencing space, digital PCR (ddPCR), is a highly sensitive and spe-
cific technique for the detection of mutations. DNA molecules are split into droplets 
that form a water oil emulsion. Droplets are like individual test tubes or wells on 
a plate where a PCR reaction occurs from a DNA template. Each drop is analyzed 
or read to determine the fraction of positive droplets in the total sample and can 
accurately and sensitively quantify a mutation. The creation of thousands of drops 
means that a single sample can generate thousands of data, which are statistically 
analyzed. For digital PCR the assays are limited to specific single mutations or sets 
of highly related mutations at the same locus. The analysis of broader genomic 
regions using ddPCR is not feasible. However, discriminatory multiplex ddPCR 
assays can be developed, which enable very rapid and cost-effective monitoring for 
a limited number of mutations in serial plasma samples [28].
4.3 Sanger capillary sequencing
Sanger sequencing is a DNA sequencing method based on the selective incorpo-
ration of chain-terminating dideoxynucleotides by DNA polymerase during in vitro 
DNA replication [29, 30]. This method was first developed by Frederick Sanger 
and colleagues in 1977, and became the most widely used sequencing method for 
over 40 years. However, the Sanger method remains widely used for smaller-scale 
projects and for validation of NGS results.
4.4 Next-generation sequencing (NGS)
In this decade, the treatment of cancer patients has evolved with the addition 
of new massive sequencing technologies. This contributed to the study of tumor 
biology with an accurate and highly covered diagnostic method that allows the 
selection of those patients likely to benefit most from target-specific targeted 
therapies. NGS, massively parallel or deep sequencing, refers to a DNA sequencing 
technology that has revolutionized genomic research. NGS can be used to sequence 
the whole human genome within a single day. In contrast, the previous Sanger 
sequencing technology used to decipher the human genome took over a decade to 
deliver the final draft [31]. Over the last years, massively parallel sequencing has 
rapidly evolved and has now transitioned into molecular pathology routine labo-
ratories. This is an interesting platform for the simultaneous analysis of multiple 
genes with low input material. Therefore, laboratories working with FFPE mate-
rial and high sample throughput largely require high-quality DNA obtained from 
automated DNA extraction systems. The spectrum of DNA variation in a human 
genome comprises small base changes (substitutions), insertions and deletions of 
DNA, large genomic deletions of exons or whole genes and rearrangements, such as 
Pathology - From Classics to Innovations
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inversions and translocations. Traditional Sanger sequencing focuses on the discov-
ery of substitutions and small insertions and deletions.
There are a number of different NGS platforms using different sequencing 
technologies, but all these platforms sequence millions of small fragments of DNA 
in parallel. The aim of bioinformatics analyses is to piece together these fragments 
by mapping the individual reads to the human reference genome (pipelines). Each 
of the three billion bases in the human genome is sequenced several times, in order 
to provide accurate data and an insight into unexpected DNA variation. NGS can 
be used to sequence either whole genomes or specific genomic areas of interest, 
including all 22,000 coding genes, the whole-genome sequencing (WGS), the 
whole exome sequencing (WES). This is a genomic technique for sequencing all 
of the protein-coding regions of genes in a genome, known as the exome; or small 
numbers of individual genes (NGS panels).
Parallel sequencing requires target enrichment, which is a pre-sequencing step 
that only allows part of a whole-genome be sequenced, or regions of interest, without 
sequencing the entire genome of a sample. The two most commonly used techniques 
for NGS target enrichment are capture hybridization and amplicon-based (multiplex 
PCR). In capture hybridization, genomic DNA is cut to produce small fragments 
that join sequencer-specific adaptors and indexes to prepare the library, and then 
the sample is hybridized with biotinylated RNA library primers. Target regions are 
extracted with magnetic streptavidin beads, amplified and sequenced. Capture 
hybridization is a screening method for large genetic panels and a large DNA input 
(more than 1 ug DNA), with a laborious and complex workflow, but a better perfor-
mance. In amplicon sequencing, custom oligo capture probes are designed to flank 
DNA specific regions without fragmenting. Extension/ligation takes place between 
hybridized probes. Finally, the uniquely labeled amplicon library is ready for cluster 
generation and sequencing. The extension/ligation occurs between hybrid probes 
which determines a uniquely tagged amplicon library ready for cluster generation and 
sequencing. Amplification sequencing is used for small gene panels or somatic muta-
tion hotspots (target from kb to Mb), with lower DNA input (100 ng). It has a simple 
and fast protocol (combining sample preparation and enrichment in one assay), but 
it is more liable to false positive and negative calls. Considering the WGS method in 
the same fresh and FFPE samples, hybrid capture sequencing showed higher sensi-
tivity compared to amplicon sequencing, while maintaining 100% specificity using 
Sanger sequencing as a validation method. Amplicon method has higher target rates. 
Hybridization capture-based approaches demonstrated that many of them could 
be false positives or negatives [32]. These results reveal advantages and disadvan-
tages of both methods. Therefore, a greater number of trials must be undertaken to 
demonstrate both clinical usefulness and socioeconomic benefits. On occasions, an 
extremely sensitive method is not worth using given its clinical implications.
The basic premise of cancer genomics is that cancer is caused by somatically 
acquired mutations, and is therefore a disease of the genome. Capillary-based cancer 
sequencing has been ongoing for over a decade. However, these investigations were 
restricted to relatively few samples and small numbers of candidate genes. Tumor 
heterogeneity and the addition of new molecular targets have become a challenge 
that needs a multidisciplinary approach and learning, with the study of the molecu-
lar profile of the tumor at the genomic (DNA), transcriptomic (RNA) or protein 
(protein) level. NGS technique is a useful and novel tool for the study of molecular 
profile from DNA/RNA. To do the library using amplicon methods it is only nec-
essary to obtain 10 ng of DNA just from the tumor, and 10 ng of RNA, which is 
feasible, even from small samples, fixed in formalin and included in paraffin [31].
Thus, three of the major technical drawbacks of the massive analysis required for 
the approach of multiple specific biomarkers for the treatment are resolved. These 
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drawbacks include the small size of biopsy sample and material scarcity, paraffin fixa-
tion of tissues and its effect on DNA/RNA and the impossibility to collect and store 
fresh material in standard clinical practice. Therefore, this type of studies is necessary 
to optimize the quality of patient care, avoiding errors and false positives or negatives. 
Thus, the use of NGS panels with small and overlapping amplicons would solve all 
these drawbacks, always associated with a bioinformatics algorithm (pipeline) that 
allows the overlap of the fragments obtained with a reference sequence.
5. In-depth study of molecular alterations
The prevalence of molecular alterations with targeted treatment may vary accord-
ing to different variables, such as the region of the world, race and gender [33, 34]. 
About 86% of tumors have molecular alterations that can potentially be treatable with 
approved or developing drugs, of which approximately 30% have clinically available 
drugs. The distribution of these alterations in patients with metastatic disease varies 
compared to those observed in resected tumors at earlier stages [35].
Different analysis options may be combined according to the molecular target 
to be identified, the type of molecular alteration and the type of sample required. 
Regarding the KRAS gene, a GTPase which functions as an upstream regulator 
of the MAPK and PI3K pathways, it is frequently mutated in various cancer types 
including pancreatic, colorectal and lung cancers [36].
KRAS was one of the first markers to be used as a therapeutic target in colorectal 
cancer (CRC) in clinical practice since the approval of cetuximad in the second 
line in 2008. Both the European Medical Agency (EMEA) and the Food and Drug 
Administration (FDA) in 2008 approved the use of anti-EGFR monoclonal antibod-
ies in patients with tumors with non-mutated KRAS (KRAS-wt). The selection of 
patients for anti-EGFR treatment based on the mutational status of codons 12 and 13 
of the KRAS gene is highly specific to non-responder patients. At that time, the tissue 
was not macro-dissected, biopsies containing more than 70% of tumor cells were 
processed by sequencing for the reasons mentioned above, and approximately 30% of 
cases could not be evaluated since they failed to meet these criteria. Codon 12 and 13 
of exon 2 of the KRAS gene were studied and the type of mutation found was irrel-
evant. For exon 2, 40% of the CRC patients were mutated and 60% were wt (codon 
12 and 13). Results showed that 95% of patients with mutated CRC for KRAS did not 
benefit from anti-EGFR treatment. However, it was not sensitive enough because 
only half of patients with KRAS-wt tumors responded to treatment [37]. Then, the 
59 and 61 codons of exon 3 and the 117 and 146 codons of exon 4 were eventually 
added. Automated qPCR methods were developed, which covered these hot-spots 
and dually reported wt or mutated. Nowadays, these binomial methods (wt/mutated) 
would not serve to identify the G12C amino acid change (c.34G > T p.Gly12Cys). 
Target therapies like KRAS G12C covalent inhibitors, such as AMG-510, are currently 
in early phase clinical trials and show promising results for the treatment of KRAS 
G12 mutant lung cancer patients. However, KRAS G12C colorectal cancer patients 
have not shown the same response. KRAS mutation testing was carried out using 13 
technologies and assays. Limits of detection (LD) of the 13 methods were showed in 
the following table. Of 13 assays evaluated in this work, 9 showed relatively similar 
levels of accuracy and reliability in detecting KRAS mutations at low levels with 
varying sensitivities (50 copies mutant allele frequency by each technology). The best 
performances were obtained by three assays: Oncomine Focus Assay, Idylla KRAS 
Mutation Test and UltraSEEK, with high sensitivity and specificity across the entire 
cell line panel. The worst performances in detection were Illumina Nextera Rapid 












Real-time quantitative PCR MALDI-TOF NGS ddPCR Sanger
1 2 3 4 5 6 7 8 9 10 11 12 13
LD 5 5 5 10 0,1 5 5 5 10 5 5 0.001 20
1. therascreen KRAS RGQ PCR Kit
2. cobas KRAS Mutation Test




7. Oncomine Focus Assay
8. Sentosa SQ NSCLC Panel
9. Illumina Nextera Rapid Capture Custom Lung Panel
10. Ion AmpliSeq Cancer Hotspot Panel v2
11. TruSight Tumor 15 panel
12. PrimePCR ddPCR Mutation Assays KRAS
13. ABI3730 sequencing
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The NGS study may infer biological mechanisms that may explain primary resis-
tance (absence of response to tyrosine kinase inhibitors and disease progression as 
a better response). This information is required for decision-making of the allelic 
frequency data for DNA sequence variants, amplified reads for fusions, or the num-
ber of copies of amplified genes, since in order to determine that a sequence variant 
has a clear oncogenic role in the tumor, its representative presence is required. One 
of the most common false positives with NGS, partly due to its high sensitivity, is 
the amplification and sequencing of variants from clonal hematopoiesis. Obtaining 
DNA from FFPE is a methodology used for more than decades, with satisfactory 
results, since the DNA obtained was degraded by fixation-paraffinization process, 
as well as its opposite effect which is the deparafinization of tissue. Obtaining 
RNA from this type of sample is most controversial given its increased lability, 
and was recently accepted due to the incorporation of new purification strategies. 
Therefore, obtaining RNA from FFPE was the greatest difficulty of this DNA/
RNA NGS method, and required this minimum learning curve to achieve optimal 
80% performance (Figure 3). The effectiveness of RNA isolation was calculated, 
taking into account criterion >5000 reads as evaluable sample, for each run/chip. 
Increased performance was achieved as the long runs occurred. The initial yield 
was less than 50%, reaching 80% maximum, because the fixation of the tissue as 
well as the deparanization process are counterproductive effects for obtaining RNA. 
Pre-analytical pathological processes for NGS take a crucial role.
This has been especially relevant in RNA sequencing from paraffin block. A 
learning curve is required before using this methodology in the clinical field. The 
acquisition of macromolecules management is critical. On the other hand, multidis-
ciplinary work is crucial for the correct interpretation of the information provided 
by these new technologies. Crude data alone, without associated bioinformatics 
information, should not be used for the treatment of patients. The main pitfall of 
NGS in the clinical setting is the infrastructure, such as computer capacity and 
Figure 3. 
RNA performance (1= > 5000 reads, 0 < 5000 reads).
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storage, and personnel trained in comprehensive analyses and interpretation of the 
subsequent data. In addition, and in order to obtain clinically relevant information 
in a clear and robust interface, the volume of data needs to be proficiently man-
aged. However, to make NGS cost effective one would have to run large batches of 
samples which may require supra-regional centralization. The objective of imple-
menting new technologies is to develop personalized treatment strategies that result 
in prolongation of survival of patients with a better quality of life.
6. Conclusion
The analysis of the biology of tumors, using NGS, allows to expand the number 
of molecular alterations to be studied, and allows to detect more patients who can 
benefit from targeted treatments, modifying the survival in patients with detected 
and treated molecular alterations. A continuous and inexorable shift in surgical 
pathology can be observed, with histological diagnosis being just one of its compo-
nents. The molecular profile is nowadays an essential tool for anatomic pathology 
practice, which invariably requires highly trained specialists. The in-depth study of 
molecular alterations in patients allows optimizing molecular diagnosis and selecting 
patients to receive novel treatments, targeted against specific molecular targets for 
the clinical benefit of patients, through a multidisciplinary approach and learning.
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